The clinical trial, sponsored by The General Hospital of Western Theater Command in collaboration with Yake Biotechnology Ltd., aims to address the significant unmet medical need for patients with relapsed refractory neuroblastoma. With GD2 being a highly specific target for neuroblastoma immunotherapy, the successful development of GD2-CAR T cells could position the sponsors favorably in the competitive landscape of CAR T-cell therapies. The trial is currently recruiting, with an estimated enrollment of 30 patients, indicating a focused approach to early-stage development. The market for neuroblastoma therapies is underserved, particularly for high-risk patients, suggesting potential for substantial commercial opportunity if efficacy and safety are demonstrated.